Fig. 8: LINC00969 regulates resistance to gefitinib in vivo. | Cell Death & Disease

Fig. 8: LINC00969 regulates resistance to gefitinib in vivo.

From: LncRNA LINC00969 promotes acquired gefitinib resistance by epigenetically suppressing of NLRP3 at transcriptional and posttranscriptional levels to inhibit pyroptosis in lung cancer

Fig. 8: LINC00969 regulates resistance to gefitinib in vivo.

PC9/GR cells were injected into 12 nude mice. Once tumours were palpable, and intratumorally administered with in vivo-optimized si-LINC00969 and control (5 nmol per injection) once every 4 days. In addition, Gefitinib (25.0 mg/kg) or the corresponding control treatment was administered to the mice once a day. A Pictures of the tumours are shown and were compared among the groups. B Every 4 days, the tumour volume was calculated. C Tumour weights were calculated and presented as the mean tumour weight ± S.D. (standard deviation) values. D The tumour sections were subjected to H&E staining and immunohistochemical for Ki67, NLRP3 and (NT-)GSDMD. E Proposed model in which LINC00969 mediates gefitinib resistance and tumorigenesis in NSCLC. All bars show the mean ± SD of three independent experiments. **P < 0.01.

Back to article page